Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Forma Therapeutics Holdings Inc.
Headquarters: Watertown, MA, United States of America
Website: N/A
Year Founded: 2007
Status: Acquired
BioCentury | Apr 11, 2023
Management Tracks
Legend hires Koneru as CMO
Plus: Erasca promotes Morris, Lovejoy and updates from Poseida, Mithra, Tune, Cellarity and more
BioCentury | Mar 3, 2023
Finance
March 2 Quick Takes: MorphoSys laying off staff, ending preclinical work
Plus: Flamingo teaming up with Dynacure and updates from Debiopharm, Aldeyra, Checkpoint and more
BioCentury | Sep 1, 2022
Deals
$1.1B Forma buyout gives Novo advanced sickle cell asset with potential for accelerated approval
Latest takeout in SCD is the culmination of Forma’s realignment around its internal pipeline
BioCentury | Aug 3, 2022
Finance
Aug. 2 Quick Takes: Yescarta label expansion buoys Gilead’s 2Q22 sales
Plus Megaround for Sironax, and updates from Eleven, Roche, Axcella, Phathom, and more
BioCentury | Jun 30, 2022
Management Tracks
FDA names Bumpus chief scientist, Marston CMO
Plus Beyer becomes CEO at Kures, and updates from NGM, Apexigen, Achilles and more
BioCentury | Apr 6, 2022
Management Tracks
Sabatini out at MIT
Plus Avidity expands role of MacLean and updates from Exscientia, eFFECTOR, Sofinnova and more
BioCentury | Dec 1, 2021
Management Tracks
Grauer becomes CMO at Federation Bio
Plus: LabGenius, 23andMe, Vifor, Immunovia, Forma and more
BioCentury | Oct 17, 2020
Finance
Novartis Venture Fund’s move to earlier, riskier bets starting to pay off
NVF’s 2020 liquidity events could be a sign that its strategic shift and new team are moving in the right direction
BioCentury | Jun 20, 2020
Finance
Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum
Beijing-based Genetron debuts with $1.4B valuation as quartet of biotechs price offerings
BioCentury | Jun 2, 2020
Finance
CAR T play Legend looks to lead trio of biotechs onto NASDAQ
Pliant, Lantern also hope to price IPOs this week
Items per page:
1 - 10 of 10